Skip to main content
Premium Trial:

Request an Annual Quote

Acacia Will Use $2.9M from Stock Sale to Fund Dx, Product Development at CombiMatrix

NEW YORK, June 30 (GenomeWeb News) - CombiMatrix parent Acacia Research plans to raise $2.9 million in a private placement of its Acacia Research-CombiMatrix common stock, the company said today.

 

The cash will go to Acacia's balance sheet, it will help fund CombiMatrix's entry into the molecular diagnostics market, and it will support the company's "long-term strategy" of developing new products for its CustomArray line, the company said in a statement.

 

Terms of the deal call for Acacia to sell 1,300,444 shares of it's the common stock at $2.25 per share to an undisclosed "select" group of institutional investors. The closing of the offering is expected to take place on July 5, subject to certain customary closing conditions.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.